Top

Published in:

Open Access 01-10-2016 | Original Article

Association of variants in BAFF (rs9514828 and rs1041569) and BAFF-R (rs61756766) genes with the risk of chronic lymphocytic leukemia

Authors: Monika Jasek, Agnieszka Bojarska-Junak, Marta Wagner, Maciej Sobczyński, Dariusz Wołowiec, Jacek Roliński, Lidia Karabon, Piotr Kuśnierczyk

Published in: Tumor Biology | Issue 10/2016

Abstract

The B-cell activator factor (BAFF)/BAFF receptor (BAFF-R) axis seems to play an important role in the development and progression of chronic lymphocytic leukemia (CLL). Here, we investigated the association of eight single nucleotide polymorphisms (SNPs) in the BAFF (TNFSF13B) and BAFF-R (TNFRSF13C) genes with risk of sporadic CLL in a group of 439 CLL patients and 477 controls. We also examined the correlation between selected SNPs and CLL clinical parameters as well as BAFF plasma levels and intracellular BAFF expression. Our results point to a possible association between the rs9514828 (CT vs. CC + TT; OR = 0.74; CI 95 % = 0.57; 0.97; p = 0.022) and rs1041569 (AT vs. AA + TT; OR = 0.72; CI 95 % = 0.54; 0.95; p = 0.021) of BAFF gene and rs61756766 (CC vs. CT; OR = 2.03; CI 95 % = 1.03; 3.99; p = 0.03) of BAFF-R gene and CLL risk. Additionally, we observed that homozygotes rs1041569 AA and TT had a slightly higher risk (HR = 1.12) for the need of treatment in comparison to AT heterozygotes. In conclusion, our results indicate that SNPs in BAFF and BAFF-R genes may be considered as potential CLL risk factors.

Available only for authorised users

Haiat S, Billard C, Quiney C, Ajchenbaum-Cymbalista F, Kolb JP. Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology. 2006;118(3):281–92.CrossRefPubMedPubMedCentral

Pflug N, Bahlo J, Shanafelt TD, Eichhorst BF, Bergmann MA, Elter T, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014;124(1):49–62.CrossRefPubMedPubMedCentral

Ferrer G, Hodgson K, Montserrat E, Moreno C. B cell activator factor and a proliferation-inducing ligand at the cross-road of chronic lymphocytic leukemia and autoimmunity. Leuk Lymphoma. 2009;50(7):1075–82.CrossRefPubMed

Mackay F, Schneider P. Cracking the BAFF code. Nat Rev Immunol. 2009;9(7):491–502.CrossRefPubMed

Yang S, Li JY, Xu W. Role of BAFF/BAFF-R axis in B-cell non-Hodgkin lymphoma. Crit Rev Oncol Hematol. 2014;91(2):113–22.CrossRefPubMed

Hildebrand JM, Luo Z, Manske MK, Price-Troska T, Ziesmer SC, Lin W, et al. A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling. J Exp Med. 2010;207(12):2569–79.CrossRefPubMedPubMedCentral

Wang SS, Purdue MP, Cerhan JR, Zheng T, Menashe I, Armstrong BK, et al. Common gene variants in the tumor necrosis factor (TNF) and TNF receptor superfamilies and NF-kB transcription factors and non-Hodgkin lymphoma risk. PLoS One. 2009;4(4):e5360.CrossRefPubMedPubMedCentral

Bojarska-Junak A, Hus I, Chocholska S, Wasik-Szczepanek E, Sieklucka M, Dmoszynska A, et al. BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: correlation with biological and clinical features. Leuk Res. 2009;33(10):1319–27.CrossRefPubMed

Novak AJ, Grote DM, Ziesmer SC, Kline MP, Manske MK, Slager S, et al. Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(6):983–7.CrossRef

10.

Novak AJ, Slager SL, Fredericksen ZS, Wang AH, Manske MM, Ziesmer S, et al. Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. Cancer Res. 2009;69(10):4217–24.CrossRefPubMedPubMedCentral

11.

Molica S, Digiesi G, Battaglia C, Cutrona G, Antenucci A, Molica M, et al. Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia. Eur J Haematol. 2010;85(4):314–20.CrossRefPubMed

12.

Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 2013;24(3):203–15.CrossRefPubMed

13.

Lahiri A, Pochard P, Le Pottier L, Tobon GJ, Bendaoud B, Youinou P, et al. The complexity of the BAFF TNF-family members: implications for autoimmunity. J Autoimmun. 2012;39(3):189–98.CrossRefPubMed

14.

Jasek M, Wagner M, Sobczynski M, Wolowiec D, Kuliczkowski K, Woszczyk D, et al. Polymorphisms in genes of the BAFF/APRIL system may constitute risk factors of B-CLL—a preliminary study on a Polish population. Tissue Antigens. 2015;86(4):279–84.

15.

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–56.CrossRefPubMedPubMedCentral

16.

Nossent JC, Lester S, Zahra D, Mackay CR, Rischmueller M. Polymorphism in the 5’ regulatory region of the B-lymphocyte activating factor gene is associated with the Ro/La autoantibody response and serum BAFF levels in primary Sjogren’s syndrome. Rheumatology. 2008;47(9):1311–6.CrossRefPubMed

17.

Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res. 2009;37 :W600–5.Web Server issueCrossRefPubMedPubMedCentral

18.

Yuan HY, Chiou JJ, Tseng WH, Liu CH, Liu CK, Lin YJ, et al. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res. 2006;34 :W635–41.Web Server issueCrossRefPubMedPubMedCentral

19.

Rousseeuw PJ, Croux C. Alternatives to the median absolute deviation. JASA. 1993;88:1273–83.CrossRef

20.

Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol. 1995;12(5):921–7.PubMed

21.

Salanti G, Amountza G, Ntzani EE, Ioannidis JP. Hardy-Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet: EJHG. 2005;13(7):840–8.CrossRefPubMed

22.

Zhai K, Tian X, Wu C, Lu N, Chang J, Huang L, et al. Cytokine BAFF gene variation is associated with survival of patients with T-cell lymphomas. Clin Cancer Res: Off J Am Assoc Cancer Res. 2012;18(8):2250–6.CrossRef

23.

de Almeida ER, Petzl-Erler ML. Expression of genes involved in susceptibility to multifactorial autoimmune diseases: estimating genotype effects. Int J Immunogenet. 2013;40(3):178–85.CrossRefPubMed

24.

Nezos A, Papageorgiou A, Fragoulis G, Ioakeimidis D, Koutsilieris M, Tzioufas AG, et al. B-cell activating factor genetic variants in lymphomagenesis associated with primary Sjogren’s syndrome. J Autoimmun. 2014;51:89–98.CrossRefPubMed

25.

Emmerich F, Bal G, Barakat A, Milz J, Muhle C, Martinez-Gamboa L, et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol. 2007;136(2):309–14.CrossRefPubMed

26.

Gragnani L, Piluso A, Giannini C, Caini P, Fognani E, Monti M, et al. Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fcgamma receptors. Arthritis Rheum. 2011;63(5):1446–51.CrossRefPubMed

27.

Malheiros D, Petzl-Erler ML. Individual and epistatic effects of genetic polymorphisms of B-cell co-stimulatory molecules on susceptibility to pemphigus foliaceus. Genes Immun. 2009;10(6):547–58.CrossRefPubMed

28.

Sandelin A, Wasserman WW, Lenhard B. ConSite: web-based prediction of regulatory elements using cross-species comparison. Nucleic Acids Res. 2004;32 :W249–52.Web Server issueCrossRefPubMedPubMedCentral

29.

Eguchi T, Prince T, Wegiel B, Calderwood SK. Role and regulation of myeloid zinc finger protein 1 in cancer. J Cell Biochem. 2015;116(10):2146–54.CrossRefPubMed

30.

Beishline K, Azizkhan-Clifford J. Sp1 and the ‘hallmarks of cancer’. FEBS J. 2015;282(2):224–58.CrossRefPubMed

31.

Faustova M, Plestilova L, Hulejova H, Pecha O, Betteridge Z, Mann H, Putova I, Vencovsky J, Novota P, Krystufkova O. Genetic variation in promoter sequence of B-cell-activating factor of the TNF family (BAFF) in patients with idiopathic inflammatory myopathies (IIM) http://ard.bmj.com/content/72/Suppl_1/A51.3.full.pdf.

32.

Lin JD, Yang SF, Wang YH, Fang WF, Lin YC, Lin YF, et al. Analysis of associations of human BAFF gene polymorphisms with autoimmune thyroid diseases. PLoS One. 2016;11(5):e0154436.CrossRefPubMedPubMedCentral

33.

Boisson B, Wang YD, Bosompem A, Ma CS, Lim A, Kochetkov T, et al. A recurrent dominant negative E47 mutation causes agammaglobulinemia and BCR(−) B cells. J Clin Invest. 2013;123(11):4781–5.CrossRefPubMedPubMedCentral

34.

Frasca D, Nguyen D, Riley RL, Blomberg BB. Decreased E12 and/or E47 transcription factor activity in the bone marrow as well as in the spleen of aged mice. J Immunol. 2003;170(2):719–26.CrossRefPubMed

35.

Patel D, Chinaranagari S, Chaudhary J. Basic helix loop helix (bHLH) transcription factor 3 (TCF3, E2A) is regulated by androgens in prostate cancer cells. Am J Cancer Res. 2015;5(11):3407–21.PubMedPubMedCentral

36.

Kardava L, Yang Q, St Leger A, Foon KA, Lentzsch S, Vallejo AN, et al. The B lineage transcription factor E2A regulates apoptosis in chronic lymphocytic leukemia (CLL) cells. Int Immunol. 2011;23(6):375–84.CrossRefPubMedPubMedCentral

37.

Ansell SM, Novak AJ, Ziesmer S, Price-Troska T, LaPlant B, Dillon SR, et al. Serum BLyS levels increase after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma. Am J Hematol. 2009;84(2):71–3.CrossRefPubMedPubMedCentral

38.

Eilertsen GO, Van Ghelue M, Strand H, Nossent JC. Increased levels of BAFF in patients with systemic lupus erythematosus are associated with acute-phase reactants, independent of BAFF genetics: a case-control study. Rheumatology. 2011;50(12):2197–205.CrossRefPubMed

39.

Fabris M, Quartuccio L, Vital E, Pontarini E, Salvin S, Fabro C, et al. The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers. Arthritis Rheum. 2013;65(1):88–97.CrossRefPubMed

Title: Association of variants in BAFF (rs9514828 and rs1041569) and BAFF-R (rs61756766) genes with the risk of chronic lymphocytic leukemia
Authors: Monika Jasek
Agnieszka Bojarska-Junak
Marta Wagner
Maciej Sobczyński
Dariusz Wołowiec
Jacek Roliński
Lidia Karabon
Piotr Kuśnierczyk
Publication date: 01-10-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 10/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-5182-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2016

Association of Sp1 and survivin in epithelial ovarian cancer: Sp1 inhibitor and cisplatin, a novel combination for inhibiting epithelial ovarian cancer cell proliferation

IQGAP1 gene silencing induces apoptosis and decreases the invasive capacity of human hepatocellular carcinoma cells

Different expression levels of glycans on leukemic cells—a novel screening method with molecularly imprinted polymers (MIP) targeting sialic acid

Rab23 activities and human cancer—emerging connections and mechanisms

Alternative splicing of S6K1 promotes non-small cell lung cancer survival

Tumor suppressor Fbxw7 antagonizes WNT signaling by targeting β-catenin for degradation in pancreatic cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer